导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.31% | 2896/4773 |
| 近一周 | -1.98% | 1003/5462 |
| 近一月 | -3.80% | 1968/5421 |
| 近一季 | -7.58% | 2453/5209 |
| 近半年 | -3.94% | 2371/4920 |
| 近一年 | -0.74% | 2771/4366 |
| 近两年 | 43.52% | 1709/2954 |
| 近三年 | 24.86% | 1283/2253 |
| 成立以来 | 16.87% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.39% 3173/4961 |
11.92% 2269/5312 |
- - |
- - |
| 2025 | 18.56% 2303/4813 |
-0.96% 2492/3635 |
1.67% 2239/4076 |
17.85% 2419/4524 |
-0.09% 2353/4813 |
| 2024 | 15.06% 971/3463 |
2.04% 827/2808 |
-1.58% 1079/3014 |
15.56% 1684/3129 |
-0.85% 1531/3463 |
| 2023 | -10.64% 1321/2656 |
3.34% 1214/2280 |
-4.96% 1327/2385 |
-3.27% 885/2515 |
-5.94% 1566/2655 |
| 2022 | -18.45% 711/2207 |
-13.98% 882/1919 |
6.60% 653/2016 |
-12.18% 662/2113 |
1.27% 1318/2208 |
| 2021 | 4.80% 564/1822 |
-2.62% 679/1255 |
8.35% 631/1330 |
-2.55% 579/1466 |
1.92% 752/1822 |
| 2020 | - - |
- - |
- - |
- - |
12.88% 418/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 摩根MSCI中国A股ETF联接A VS. 长安沪深300非周期A(740101) |